Cue Biopharma (NASDAQ:CUE) Announces Earnings Results

Posted by Brian Himes on Nov 13th, 2025

Cue Biopharma (NASDAQ:CUE – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03, FiscalAI reports. The firm had revenue of $2.15 million during the quarter, compared to analysts’ expectations of $2.29 million. Cue Biopharma had a negative net margin of 469.35% and a negative return on equity of 230.13%.

Cue Biopharma Price Performance

Shares of CUE traded down $0.01 during trading hours on Thursday, hitting $0.66. 2,874,847 shares of the stock were exchanged, compared to its average volume of 256,995. Cue Biopharma has a 12-month low of $0.54 and a 12-month high of $1.75. The company has a market cap of $50.34 million, a price-to-earnings ratio of -1.14 and a beta of 1.49. The stock’s 50-day moving average price is $0.75 and its two-hundred day moving average price is $0.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.60.

Institutional Investors Weigh In On Cue Biopharma

A hedge fund recently raised its stake in Cue Biopharma stock. Northwestern Mutual Wealth Management Co. grew its holdings in Cue Biopharma, Inc. (NASDAQ:CUE – Free Report) by 730.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 83,000 shares of the company’s stock after purchasing an additional 73,000 shares during the period. Northwestern Mutual Wealth Management Co. owned approximately 0.11% of Cue Biopharma worth $57,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research note on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on CUE

About Cue Biopharma

(Get Free Report)

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.